Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

ABSTRACT:

Background

We recently reported that peroxisome proliferator-activated receptor γ agonists target chronic myeloid leukemia (CML) quiescent stem cells in vitro by decreasing transcription of STAT5. Here in the ACTIM phase 2 clinical trial, we asked whether pioglitazone add-on therapy to imatinib would impact CML residual disease, as assessed by BCR-ABL1 transcript quantification.

Methods

CML patients were eligible if treated with imatinib for at least 2 years at a stable daily dose, having yielded major molecular response (MMR) but not having achieved molecular response 4.5 (MR^4.5 ) defined by BCR-ABL1/ABL1^IS RNA levels ≤ 0.0032%. After inclusion, patients started pioglitazone at a dosage of 30 to 45 mg/day in addition to imatinib. The primary objective

SUBMITTER: Rousselot P 

PROVIDER: S-EPMC5434901 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature